1.Anandarajah AP，Schwarz EM，Totterman S，et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oe

dema in patients with psoriatic arthritis. Ann Rheum Dis，2008，67：296-301.

2.Apel M，Uebe S，Bowes J，et al. Variants in RUNX3 contribute to susceptibility to psoriatic arthritis，exhibiting further common ground with ankylosing spondylitis. Arthritis Rheum. 2013；65：1224-1231.

3.Celis R，Planell N，Fernandez-Sueiro JL，et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther，2012，14：R93.

4.Cénit MC，Ortego-Centeno N，Raya E，et al. Inf l uence of the STAT3 genetic variants in the susceptibility to psoriatic arthritis and Behcet’s disease. Hum Immunol，2013，74：230-133.

5.Chandran V，Bull SB，Pellett FJ，et al. Killer-cell immunoglobulin-like receptor gene polymorphisms and susceptibility to psoriatic arthritis. Rheumatology，2014，53：233-239.

6.Chen HA，Chen CH，Lin YJ，et al. Association of bone morphogenetic proteins with spinal fusion in ankylosing spondylitis. J Rheumatol，2010，37：2126-2132.

7.Eder L，Chandran V，Pellet F，et al. Human leukocyte antigen risk alleles for psoriatic arthritis among patients with psoriasis. Ann Rheum Dis，2012，71：50-55.

8.Ellinghaus E，Stuart PE，Ellinghaus D，et al. Genome-wide metaanalysis of psoriatic arthritis identifi es susceptibility locus at REL. J Invest Dermatol，2012，132：1133-1140.

9.Gonzalez S，Martinez-Borra J，Torre-Alonso JC，et al. The MICA-A9 triplet repeat polymorphism in the transmembrane region confers additional susceptibility to the development of psoriatic arthritis and is independent of the association of Cw*0602 in psoriasis. Arthritis Rheum，1999，42：1010-1016.

10.Hampton PJ，Ross OK，Reynolds NJ. Increased nuclear beta-catenin in suprabasal involved psoriatic epidermis. Br J Dermatol，2007，157：1168-1177.

11.Hüffmeier U，Uebe S，Ekici AB，et al. Common variants at TRAF3IP2 are associated with susceptibility to psoriatic arthritis and psoriasis，Nat Genet，2010，42：996-999.

12.Jacques P，Lambrecht S，Verheugen E，et al. Proof of concept：enthesitis and new bone formation in spondyloarthritis are driven by mechanical strain and stromal cells. Ann Rheum Dis，2014，73：437-445.

13.Jongbloed SL，Lebre MC，Fraser AR，et al. Enumeration and phenotypical analysis of distinct dendritic cell subsets in psoriatic arthritis and rheumatoid arthritis. Arthritis Res Ther，2006，8：R15.

14.Keffer J，Probert L，Cazlaris H，et al. Transgenic mice expressing human tumor necrosis factor：a predictive genetic model of arthritis. EMBO J，1991，10（13）：4025-4031.

15.Kikuta J，Wada Y，Kowada T，et al. Dynamic visualization of RANKL and Th17-mediated osteoclast function. J Clin Invest，2013，123：866-873.

16.Koenders MI，Kolls JK，Oppers-Walgreen B，et al. Interleukin-17 receptor def i ciency results in impaired synovial expression of interleukin-1 and matrix metalloproteinases 3，9，and 13 and prevents cartilage destruction during chronic reactivated streptococcal cell wall-induced arthritis. Arthritis Rheum，2005，52（10）：3239-3247.

17.Koshy PJ，Henderson N，Logan C，et al. Interleukin 17 induces cartilage collagen breakdown：novel synergistic effects in combination with proinf l ammatory cytokines. Ann Rheum Dis. 2002；61（8）：704-713.18.Lories RJ，Derese I，Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest，2005，115：1571-1579.

19.Lories RJ，Luyten FP，de Vlam K. Progress in spondylarthritis. Mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther，2009，11：221.

20.Lories RJ，McInnes IB. Primed for inf l ammation：enthesis-resident T cells. Nat Med，2012，18（7）：1018-1019.

21.Lowes MA，Russell CB，Martin DA，et al. The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol，2013，34（4）：174-181.

22.Menon B，Gullick NJ，Walter GJ，et al. Interleukin-17+ CD8+ T cells are enriched in the joints of patients with psoriatic arthritis and correlate with disease activity and joint damage progression. Arthritis Rheum，2014，66：1272-1281.

23.Minamizaki T，Yoshiko Y，Kozai K，et al. EP2 and EP4 receptors differentially mediate MAPK pathways underlying anabolic actions of prostaglandin E2 on bone formation in rat calvaria cell cultures. Bone，2009，44：1177-1185.

24.Mitra A，Raychaudhuri SK，Raychaudhuri SP. Functional role of IL-22 in psoriatic arthritis. Arthritis Res Ther，2012，14（2）：R65.

25.O’Garra A. Cytokines induce the development of functionally heterogeneous T helper cell subsets.Immunity，1998，8（3）：275-283.

26.Okada Y，Han B，Tsoi LC，et al. Fine mapping major histocompatibility complex associations in psoriasis and its clinical subtypes. Am J Hum Genet，2014，95：162-172.

27.Partsch G，Wagner E，Leeb BF，et al. Upregulation of cytokine receptors sTNFR55，sTNF-R75，and sIL-2R in psoriatic arthritis synovial fl uid. J Rheumatol，1998，25（1）：105-110.

28.Qu N，Xu M，Mizoguchi I，et al. Pivotal roles of T-helper 17-related cytokines，IL-17，IL-22，and IL-23，in inf l ammatory diseases. Clin Dev Immunol，2013，2013：968549.

29.Ritchlin CT，Haas-Smith SA，Li P，et al. Mechanisms of TNF-alpha-and RANKL mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest，2003，111：821-831.

30.Seifert O，Soderman J，Skarstedt M，et al. Increased expression of the Wnt signalling inhibitor Dkk-1 in Non-lesional skin and peripheral blood mononuclear cells of patients with plaque psoriasis. Acta Derm Venereol，2014，95（4）：407-410.

31.Sherlock JP，Joyce-Shaikh B，Turner SP，et al. IL-23 induces spondylo arthropathy by acting on ROR-γ +CD3 + CD4-CD8-entheseal resident T cells. Nat Med，2012，18（7）：1069-1076.

32.Spadaro A，Scrivo R，Moretti T，et al. Natural killer cells and gamma/delta T cells in synovial fl uid and in peripheral blood of patients with psoriatic arthritis. Clin Exp Rheumatol，2004，22：389-394.

33.Stuart PE，Nair RP，Ellinghaus E，et al. Genome-wide association analysis identifi es three psoriasis susceptibility loci. Nat Genet，2010，42：1000-1004.

34.Tang F，Sally B，Ciszewski C，et al. Interleukin 15 primes natural killer cells to kill via NKG2D and cPLA2 and this pathway is active in psoriatic arthritis. PLoS One，2013，8（9）：e76292.

35.Winchester R，Minevich G，Steshenko V，et al. HLA associations reveal genetic heterogeneity in psoriatic arthritis and in the psoriasis phenotype. Arthritis Rheum，2012，64：1134-1144.

36.Zhu J，Qu H，Chen X，et al. Single nucleotide polymorphisms in the tumor necrosis factor-alpha gene promoter region alter the risk of psoriasis vulgaris and psoriatic arthritis：a meta-analysis. PloS One，2013，8：e64376.

37.Zhu KJ，Zhu CY，Shi G，Fan YM. Association of IL23R polymorphisms with psoriasis and psoriatic arthritis：a meta-analysis. Inf l amm Res，2012，61：1149-1154.

38.Zhu KJ，Zhu CY，Shi G，Fan YM. Meta-analysis of IL12B polymorphisms（rs3212227，rs6887695）with psoriasis and psoriatic arthritis. Rheumatol Int，2013，33：1785-1790.